While Dyne Therapeutics Inc has underperformed by -3.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN fell by -9.67%, with highs and lows ranging from $47.45 to $13.99, whereas the simple moving average fell by -55.91% in the last 200 days.
On December 13, 2024, Robert W. Baird started tracking Dyne Therapeutics Inc (NASDAQ: DYN) recommending Outperform. A report published by RBC Capital Mkts on November 26, 2024, Initiated its previous ‘Outperform’ rating for DYN. JP Morgan also Downgraded DYN shares as ‘Neutral’, setting a target price of $35 on the company’s shares in a report dated October 24, 2024. Chardan Capital Markets Reiterated the rating as Buy on May 21, 2024, but set its price target from $31 to $42. Morgan Stanley initiated its ‘Overweight’ rating for DYN, as published in its report on April 30, 2024. H.C. Wainwright’s report from February 20, 2024 suggests a price prediction of $36 for DYN shares, giving the stock a ‘Buy’ rating. Raymond James also rated the stock as ‘Strong Buy’.
Analysis of Dyne Therapeutics Inc (DYN)
To gain a thorough understanding of Dyne Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -68.69% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.02, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and DYN is recording an average volume of 1.27M. On a monthly basis, the volatility of the stock is set at 7.18%, whereas on a weekly basis, it is put at 6.48%, with a loss of -5.93% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.83, showing growth from the present price of $14.11, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 86.89% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DYN shares are owned by institutional investors to the tune of 86.89% at present.
